Tonghua Dongbao Alert:TP adjusted for stock split
Adjusting target price to RMB24.3 on 6:5 stock split
The 6 for 5 stock split has been effective on June 2, which increased thenumber of shares outstanding to 1,363 million. We adjust our target priceproportionately to RMB24.3 from RMB29 to reflect the stock split. Our netprofit forecasts remain unchanged, and we adjust EPS forecasts to RMB0.44and RMB0.56 for 2016 and 2017 respectively. We maintain our Buy rating.。
Valuation and risks
Our price target of RMB24.3 is based on 55x 2016E EPS of RMB0.44. Webelieve 55x is justified as its A-share biotech peers which are trading at 53x on2016E EPS with 20% growth in 2016 (vs. the 31% we model for THDB). In ourview the premium is justified by its higher growth sustainability and visibility ofinsulin franchise vs. most other therapeutics, and a compelling risk profile. Keyrisks include larger price cuts and pipeline failure.